Study: GAL-001: Adaptive Phase II in Refractory Melanoma
Phase II
· Site: Mount Halifax Oncology Center (Dr. A. Reyes)
· consented 2026-05-13
Adverse events
0
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
No adverse events recorded.
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.